610	= 40
FEB 0	7 2007
STONE OF	MERCHANICAL Port



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Te man		n dundam Ant of 1005 no re	TRAPE	e required to respond to a co	ollection of information unless it contains a	valid OMB control number.					
Section 1	perwork !				Comp	tete ij ithomi.					
		Substitute for form 14	49A/PT	О	Application Number 10/535,189						
-	INFO	DRMATION D	ISC:	LOSURE	Filing Date	September 21, 2006 Alexei SHIR et al			September 21, 2006		
	STA	TEMENT BY	APP	LICANT	First Named Inventor						
		(use as many sheets o	as nec	essary)	Art Unit	1635					
	Ì	•			Examiner Name	GIBBS, TERRA C					
Sheet	T	1	of	4	Attorney Docket Number	29770					
				U.S. PATENT	DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whe Relevant Passages or Releva Figures Appear	nt				
		Number-Kind Code ^{2 (if kz}	own)				\dashv				
							\neg				
							\neg				
	 										
	 										
	 										
	 										
	+										

		FOREIGN	PATENT DOC	UMENTS_			,		\dashv
Examiner Initials*	Cite No. 1	Foreign Patent Documents Country Code ² Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
/TCG/	1	PCT WO 01/43777	06-21-2001	Aigner et	al. ONLY	AB	STRACT	CONSI	ERF
/TCG/	2	PCT WO 94/23050	10-13-1994	Chiou et a	1				H
11001	T						 		+
				 					+
									口
Examine	l er T			1	Date		12	/06/2007	
Signature /Terra Cotta Gibbs/			<u>,</u>	Consider	ed	12/	00/2007		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes considered, include copy of copy of this form with field communication to applicant. Applicant surrique citation designation number (optional). See kinds codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (MIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language

by the appropriate symbols as indicated on the document of the

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE promotion unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	Act of 1995, no persons are required to respond to a collection of ir	formation unless it contains a valid ON	lete if Known							
	Sub	stitute for form 1449A/PTO	Application Number	10/535,189							
	INFOR	MATION DISCLOSURE	Filing Date	September 21, 2	006						
		EMENT BY APPLICANT	First Named Inventor	Alexei SHIR et	al						
				1635							
	(use	e as many sheets as necessary)	Group Art Unit								
			Examiner Name	GIBBS, TERRA	· ·						
Sheet	2	of 4	Attorney Docket Number	29770							
	- -	OTHER PRIOR ART – NON PATEN	T LITERATURE DOCUM	ENTS							
Examiner	Cite	Leader to a series of the outbox (in CARITAL LETTERS)	title of the article (when appropris	ate), title of the	3						
Initials	No.	item (book, magazine, journal, serial symposium, cata publisher, city and/or cour	ilog, etc.) date, page(s), volume-iss	sue number(s),	T ²						
	3	Ogric et al. "DNA /Polyethylenimine Transfer	ction Particles: Influence of	Ligands,							
	3	Ogris et al. "DNA/Polyethylenimine Transfection Particles: Influence of Ligands, Polymer Size, and PEGylation on Internatlization and Gene Expression", AAPS									
/TCG/	1	PharmSci 3/3): Article 21: 1-11 2001		i							
	4	Sosnowski et al. "Targeting DNA to Cells wi	ith Basic Fibroblast Growth	Factor							
	'	(FGF2)" Journal of Biological Chemistry 27	/1(52): 33647-33653, 1 <u>996.</u>								
	5	Yu et al. "The Contribution of Poly-L-Lysine	e. Epidermal Growth Factor	and							
		Streptavidin to EGF/PLL/DNA Polyplex For	mation", Gene Therapy 5:	1235-1243,							
		1008									
	6	Shir et al. "Efficient Killing of Glioblastoma	Shir et al. "Efficient Killing of Glioblastoma and Other Cancers by Cancer Specific								
		Transfection of dsRNA"		of Double							
	7	Shir et al. "Inhibition of Glioma Growth by	Tumor-Specific Activation	ion of Double-							
	Stranded RNA-Dependent Protein Kinase PKR", Nature Biotechnology 20(9): 895-										
		900, 2002. Abstract. Merdan et al. "Prospects for Cationic Polyme	ers in Gene and Oligonucle	otide Therapy							
	8	Against Cancer", Advanced Drug Delivery F	Paviews 54(5): 715-758 20	002.							
		Blessing et al. "Different Strategies for Form	eation of PEGylated EGF-C	onjugated							
1	9	PEI/DNA Complexes for Targeted Gene De	livery" Bioconjugate Chem	nistry, 12(4):							
		529-537, 2001. Abstract.	nvoly , DieceligaBase enter								
	10	Bettinger et al. "Peptide-Mediated RNA Del	ivery: A Novel Approach for	or Enhanced							
	110	Transfection of Primary and Post-Mitotic Ce	ells", Nucleic Acids Research	ch, 29(18):							
		3882-3891 2001 Abstract.									
	11	Livet at "Double-Stranded Ribonucleic Ac	id (RNA) Induces β-Cell Fa	s Messenger							
1	1	RNA Expression and Increases Cytokine-Inc	duced β-Cell Apoptosis", E	ndocrinology,							
		142(6): 2593-2599, 2001, Abstract.									
	12	Shir et al "FGF Recentor-Targeted Syntheti	ic Double-Stranded RNA E	liminates							
		Glioblastoma, Breast Cancer, and Adenocar	cinoma Tumors in Mice", P	Los							
		Medicine, 3(1/e6): 0125-0135, 2006.	D.								
	13	Bansal et al. "Gene Therapy for Brain Tumo	ors", Current Oncology Rep	orts, 2: 403-							
		472, 2000.	1 Wishin HIW 1 Motery	Protein That							
Bukrinsky et al. "A Nuclear Localization Signal Within HIV-1 Matrix Pro Governs Infection of Non-Diving Cells", Nature, 365: 666-669, 1993.				1 TOTOLI TIME							
		Governs Infection of Non-Diving Cells", Na	duic, 303. 000-007, 1773.	th Factor in							
	15	Eriksdotter Joenhagen "Intracerebroventrice Three Patients With Alzheimer's Disease", I	Dementia and Geriatric Coo	nitive							
		Inree Patients With Alzheimer's Disease", I		,							
V		Disorders, 9: 246-257, 1998. Farrell et al. "Interferon Action:Two Distinctions Di	ct Pathways for Inhibition o	f Protein							
	16	Synthesis by Double-Stranded RNA", Proc.	Natl. Acad. Sci. USA. 75(12): 5893-							
/TCG/		5897, 1978.		·							

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English tanguage Translation is attached.

1. Applicant's unique citation designation number (optional). 3. Applicant is to place a check mark here if English tanguage Translation is attached.

1. Applicant's unique citation designation number (optional). 3. Applicant is to place a check mark here if English tanguage Translation is attached.

1. Applicant's unique citation is exturned by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including user preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperw	ork Reduction	Act of 1995, no persons ar	e require	d to respond to a collection of infor	mation unless it contains a valid ON	dB control number. ete if Known		
Substitute for form 1449A/PTO				Application Number				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Filing Date September 21, 200 First Named Inventor Alexei SHIR et al		, 2006	
							t al	
					Group Art Unit	1635		
	(us	e as many sheets as	neces	sary)		GIBBS, TERF	RAC	
			_		Examiner Name	<u> </u>		
Sheet	3		of	4	Attorney Docket Number			
	- 	OTHER P	RIOR	ART - NON PATENT	LITERATURE DOCUM	ENTS		
Examiner Initials	Cite No.1	Include name of th item (book, magaz	e author ine, jou	(in CAPITAL LETTERS), tit rnal, serial symposium, catalog publisher, city and/or country	le of the article (when appropria g, etc.) date, page(s), volume-iss	ue number(s),	T ²	
	17	Gallay et al "HI	V Nuc	lear Import Is Governed	by the Phosphotyrosine-	Mediated		
/TCG/	''	Binding of Matri	ix to th	e Core Domain of Integr	rase", Cell, 83: 569-576,	1995.		
	18	George "Platelet	-Deriv	ed Growth Factor Recep	itors: A Therapeutic Targe	et in Solid		
	"	Tumors" Semin	ars in (Oncology, 28(5/Suppl.1'	7): 27-33, 2001.			
	19	Giles "The Vasc	ular Fi	dothelial Growth Factor	r (VEGF) Signaling Pathy	vay: A		
		Therapeutic Targ	get in I	Patients With Hematolog	gic Malignancies", The Or	ncologist,		
		6(Suppl.5): 32-3	9, 200	1.		d C. Iver		
	20	Iordanov et al. ".	Activa	tion of P38 Mitogen-Act	tivated Protein Kinase and	ditic Virus:		
		NH2-Terminal k	Cinase	by Double-Stranded RN	A ltametive Pathways"	uitis viius. Molecular		
		Involvement of RNase L, Protein Kinase R, and Alternative Pathways", Molecular						
	21	& Cell Biology, 31: 123-138, 1999.						
	 							
	22	Kim et al. "Epidermal Growth Factor Receptor Blology, Current Opinion in						
Oncology, 13(6): 506-513, 2001. 23 Lappi "Tumor Targeting Through Fibroblast Growth Factor Receptors", S					Seminars in			
	23	Cancer Biology	6.27	9-288. 1995.				
	24	Magane et al "T	mig R	esistance of Human Glic	blastoma Cells Conferred	by A		
	27	Tumor-Specific	Mutar	nt Enidermal Growth Fac	ctor Receptor Through Mo	odulation of		
	1	Bcl-XL and Cas	spase-3	-Like Proteases", Proc.	Natl. acad. Sci. USA, 95:	5724-5729,		
	j	1008					ONLY	
	25	Nakamura et al.	"Effe	ct of Interferon Inducer (Poly ICLC) in the Treatm	nent of		
		Malignant Brair	ı Tumo	or", No To Shinkei, 34(3): 267-273, 1982. Abstrac	ct. Article in	ABSTRACT	
		Japanese. Abstr	act in	English.	Francisco Commo	n in Human	CONSIDER	
	26	Nishikawa et al	. <u>"A</u> M	utant Epidermal Growth	Factor Receptor Commo	91 111 Fullian		
			Enna	ncea lumorgenicity, Pi	oc. Natl. Acad. Sci. USA	, , , , , , , , , , , , , , , , , , , ,		
		7731, 1994.	- 2.6	A Sustame Modulation o	f Viral and Cellular Proce	sses Through		
1	27	Player et al. "If	10 Z-3/	A System. Ividualism of Degradation Degradation Pharmaco	ological Therapy, 78(2): 5	5-113, 1998.		
	28	Posen "Angiog	enecic	Inhibition in Solid Tume	ors", Cancer Journal, 7(Su	ippl.3): 120-		
	28	128 2001				·		
\	29	Salazar et al "I	ono-T	erm Treatment of malig	nant Gliomas With Intran	nuscularly		
V	47	Administered P	olvino	sinic-Polycytidylic Acid	l Stabilized With Polylysi	ne and	1	
v		Carboxymethyl	cellulo	se: An Open Pilot Study	", Congress of Neurologi	cal Surgeons,		
/TCG/		38(6): 1096-110	04, 19	96.				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

1. Applicant's unique citation is exquired by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449A/PTO 10/535,189 Application Number September 21, 2006 INFORMATION DISCLOSURE Filing Date STATEMENT BY APPLICANT Alexei SHIR et al First Named Inventor 1635 Group Art Unit (use as many sheets as necessary) GIBBS, TERRA C Examiner Name Attorney Docket Number 29770 Sheet OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite Examiner item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), $\mathbf{T}^{\mathbf{2}}$ No.1 Initials publisher, city and/or country where published. Shir et al. "Gene Therapy for Glioblastoma: Future Perspective for Delivery Systems 30 and Molecular Targets", Cellular and Molecular Neurobiology, 21(6): 645-656, 2001. /TCG/ Singh "Transferrin as A Targeting Ligand for Liposomes and Anticancer Drugs", 31 /TCG/ Current Pharmaceutical Design, 5: 443-451, 1999. Von Schwedler et al. "The Nuclear Localization Signal of the Matrix Protein of 32 Human Immunodeficiency Virus Type 1 Allows the Establishment of Infection in Macrophages and Quiescent T Lymphocytes", Proc. Natl. Acad. Sci. USA, 91: 6992-/TCG/ Wang et al. "Insulin-Like Growth Factor Receptor-1 as An Anti-Cancer Target: 33 Blocking Transformation and Inducing Apoptosis", Current Cancer Drug Targets, 2: /TCG/ 191-207, 2002.

		1	1
		Considered	12/06/2007
Signature	/Terra Cotta Gibbs/	Constant	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reference considered, whether or not citation is in conformation with the Exoderial Considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including usper on the individual case. Any comments on the amount gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.